July 17,2008
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director, President and Chief Executive Officer

SymBio Completes Phase I Clinical Trials of Sustained-Release Transdermal PatchContaining Granisetron for Chemotherapy Induced Nausea and Vomiting.

TOKYO, July 17, 2008 - SymBio Pharmaceuticals announces the completion of its Phase I studyof SyB D-0701, the transdermal patch containing granisetron currently under development by thecompany. The Phase I study consists of two studies: one for safety and pharmacokinetics inJapanese subjects, and the other to confirm further safety in a local skin irritation study byinvestigating solar urticaria and phototoxicity. The final study report will be completed this fall.
SymBio Pharmaceuticals will complete a comprehensive assessment based on the results of thetwo studies. SymBio plans to initiate a Phase II clinical study in cancer patients in the first halfof 2009.
The original licensor, Abeille Pharmaceuticals, Inc., has received Special Protocol Assessment(SPA) from US FDA and plans to start its Phase III clinical study in the U.S. in August, 2008.

SyB D-0701 is a sustained-release transdermal patch containing the 5-HT3 antagonist,granisetron, as an active ingredient which reduces nausea and vomiting in patients (CINV)
undergoing treatment with cancer chemotherapies.
Unlike conventional injection or oral type anti-emetics, SyB D-0701 is a sustained-releasetransdermal patch with an anti-emetic effect that is sustained for over 120 hours. Thus, SyB
D-0701 is expected to bring significant benefits to patients as supportive care, and to improveoverall QOL (Quality of Life) of future chemotherapy patients as cancer prevalence continues torise globally.

[Company Profile]
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, whopreviously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan, with thecorporate mission of addressing underserved therapeutic areas having high medical need inJapan, Korea, Taiwan and other Asia Pacific Rim countries. SymBio’s main focus lies in thedevelopment of drugs within three therapeutic areas: oncology, hematology and autoimmune
disease. Through its proprietary in-house search and evaluation process and experienced
management team with strong development expertise in biopharmaceuticals, SymBio is able toimplement unique strategies in the development of drug candidates, thereby bringing
much-needed therapies to market in an expeditious manner.

About Abeille Pharmaceuticals
Abeille Pharmaceuticals, Inc. is a privately-held pharmaceutical company based in Princeton,
New Jersey. The Company is focused on the formulation of products by applying advanced
delivery technologies to existing drugs. These advanced delivery technologies include oral
controlled release and transdermal delivery systems. The new products may benefit patients byrequiring a lower dose of medicine, reduced side effects and easier administration of medication,
thereby encouraging a patient to use the medication as prescribed. Abeille is dedicated to thedevelopment and commercialization of products that address unmet medical needs and improve
the quality of life for patients. The Company’s initial focus will be on drugs used to treat
oncology related discomforts (such as CINV), diabetes and metabolic disorders, and CNS.

For further information, please contact:
SymBio Pharmaceuticals Limited.
Osamu Ogawa, Ph.D.
Board Director, Senior Corporate Officer,Senior Director, Research & Development
Tel: +081(0)3 5472 1127
E-mail: Please send your inquiry through "INQUIRY" in our homepage
URL:http://www.symbiosis.co.jp